CRP and colonic disorder: These results implied that young patients with lower BMIs, no prior anti-TNF use, elevated CRP, and colonic disease would be expected to have the widest margin of difference between placebo and treatment arms; thus, trials performed in this group would be expected to have the greatest statistical power to detect evidence of efficacy.